Pfizer Inc. PFE 1.01 % ’s lower-priced version of Johnson & Johnson JNJ 0.81 % ’s blockbuster autoimmune disease drug Remicade doesn’t infringe a patent, a federal court ruled on Wednesday, potentially clearing the way for the drug’s sale in October.
J&J said it would appeal the decision and affirmed its sales projections.
11:57 Lockheed Martin's quarterly revenue up 6.6 percent27
05:35 Arkansas carries out first execution since 2005 after Supreme Court denies stay requests22
05:18 The Latest: Inmate lost consciousness quickly, witnesses say27
05:18 Arkansas Puts Ledell Lee to Death, in Its First Execution Since 200527